Michael A. Carducci, Fred Saad, Per-Anders Abrahamsson, David P. Dearnaley, Claude C. Schulman, Scott A. North, Darryl J. Sleep, Jeffrey D. Isaacson, Joel B. Nelson and for the Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer Cancer 110
Article first published online: 20 SEP 2007 | DOI: 10.1002/cncr.22996
Despite evidence of the biologic effect of atrasentan on prostate-specific antigen and bone alkaline phosphatase as markers of disease burden, in a large, randomized, placebo-controlled Phase 3 trial, atrasentan did not delay disease progression in men with metastatic hormone-refractory prostate cancer.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field